{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:54:16Z","timestamp":1787014456607,"version":"build-2736575974"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,1,4]],"date-time":"2006-01-04T00:00:00Z","timestamp":1136332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2006,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background\u2002<\/jats:bold>\n                    CXCL10 plays an important role in the initial phases of Graves\u2019 disease (GD) and autoimmune thyroiditis (AT); however, until now, CXCL10 serum levels (sCXCL10) in patients with GD have never been evaluated in relation to thyroid function and treatment.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    To evaluate sCXCL10 in GD.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design\u2002<\/jats:bold>\n                    Cross\u2010sectional.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients\u2002<\/jats:bold>\n                    One hundred and three GD, 164 AT, 20 nontoxic multinodular goitre (NTMNG), 16 toxic nodular goitre (TNG) patients and 70 healthy controls (age\u2010 and sex\u2010matched).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Measurements\u2002<\/jats:bold>\n                    We measured sCXCL10 in patients and controls, to relate this parameter to the clinical phenotype.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    Mean sCXCL10 in GD and AT patients were comparable (122\u00a0\u00b1\u00a081 and 133\u00a0\u00b1\u00a0102\u00a0pg\/ml) and significantly higher (\n                    <jats:italic>P\u00a0&lt;<\/jats:italic>\n                    \u00a00\u00b701) than in controls or NTMNG patients (73\u00a0\u00b1\u00a032 and 76\u00a0\u00b1\u00a025\u00a0pg\/ml, respectively). Hyperthyroid GD had significantly higher sCXCL10 than euthyroid or hypothyroid GD (145\u00a0\u00b1\u00a092, 107\u00a0\u00b1\u00a056 and 105\u00a0\u00b1 46\u00a0pg\/ml, respectively;\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b701). GD patients with untreated hyperthyroidism had higher sCXCL10 than hyperthyroid or euthyroid GD patients under methimazole (MMI) treatment (166\u00a0\u00b1\u00a0125, 124\u00a0\u00b1\u00a041 and 94\u00a0\u00b1\u00a035\u00a0pg\/ml, respectively;\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b7006). Comparable sCXCL10 levels were observed in newly diagnosed untreated hyperthyroid GD patients with respect to untreated patients with relapse of hyperthyroidism after a previous MMI course (176\u00a0\u00b1\u00a0125, 155\u00a0\u00b1\u00a097\u00a0pg\/ml, respectively). GD had similar sCXCL10 to AT and higher than TNG patients or controls (all age\u2010 and sex\u2010matched) (144\u00a0\u00b1\u00a081, 149\u00a0\u00b1\u00a0114, 101\u00a0\u00b1\u00a027 and 86\u00a0\u00b1\u00a044\u00a0pg\/ml, respectively;\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a00\u00b702).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions\u2002<\/jats:bold>\n                    sCXCL10 is associated with the active phase of GD in both newly diagnosed and relapsing hyperthyroid patients. The reduction in sCXCL10 in treated patients with GD may be related to the immunomodulatory effects of MMI.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2265.2006.02447.x","type":"journal-article","created":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T05:13:27Z","timestamp":1137647607000},"page":"189-195","source":"Crossref","is-referenced-by-count":52,"title":["Increase of interferon\u2010\u03b3\u2010inducible CXC chemokine CXCL10 serum levels in patients with active Graves\u2019 disease, and modulation by methimazole therapy"],"prefix":"10.1111","volume":"64","author":[{"given":"Alessandro","family":"Antonelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rotondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poupak","family":"Fallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Romagnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Martina","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Barani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,4]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80165-X"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.62.5.554"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/35065016"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03345149"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.3.510"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-002-0879-5"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64171-5"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0977"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01847"},{"key":"e_1_2_5_11_2","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1210\/jcem.86.10.7953","article-title":"Thyrocytes from autoimmune thyroid disorders produce the chemokines IP\u201010 and Mig and attract CXCR3+ lymphocytes","volume":"86","author":"Garci\u00e0\u2010L\u00f2pez M.A.","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01824.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9775"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.8.2873"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01683.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1588"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/105072503322021142"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-199804000-00008"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1420022"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.1995.5.25"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03349833"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.8.2976"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1430197"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2000.10.815"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1320668"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.1.78"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.84.2.435"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.79.2.355"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-41624"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01629.x"},{"key":"e_1_2_5_31_2","first-page":"341","article-title":"Increased serum interleukin\u20101 beta during treatment of hyperthyroidism with antithyroid drugs","volume":"26","author":"Tsatsoulis A.","year":"1996","journal-title":"European Journal of Clinical Investigation"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198411223112106"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1984.tb03456.x"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92171-B"},{"key":"e_1_2_5_35_2","first-page":"58","article-title":"Proinflammatory cytokine levels in hyperthyroidism","volume":"26","author":"Senturk T.","year":"2003","journal-title":"Clinical and Investigative Medicine"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.2.776"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5150"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(01)00261-2"},{"key":"e_1_2_5_39_2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1096\/fasebj.12.9.705","article-title":"Human IP\u201010 selectively promotes dominance of polyclonally activated and environmental antigen\u2010driven IFN\u2010gamma over IL4 response","volume":"12","author":"Gandur V.","year":"1998","journal-title":"FASEB Journal"},{"key":"e_1_2_5_40_2","first-page":"498","article-title":"Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis","volume":"72","author":"Mahad D.J.","year":"2002","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2006.02447.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2006.02447.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T14:33:07Z","timestamp":1697207587000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2006.02447.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["10.1111\/j.1365-2265.2006.02447.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2006.02447.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,4]]}}}